Mutations in ATRX and TP53 are usually identified in astrocytomas with mutant IDH, but TRET promoter variations and chromosome abnormality are generally identified in oligodendrogliomas (O-IDH) (Cancer Genome Atlas Research Network et al., 2015). Here, IDH2 is linked to oligodendroglioma.